127 results about "Staphylococcus aureus infections" patented technology

The invention belongs to the technical field of biology and relates to a staphylococcus aureus SpA5 mutant protein, and a carrier, an engineering strain, a composition or a kit containing the mutant protein, as well as an application, a preparation method, a fermentation method and a purification method of the mutant protein. The SpA5 protein provided by the invention can effectively stimulate an organism to produce protective immune response and further resist staphylococcus aureus infection, and has the advantages of strong immunogenicity, safety, no toxicity, safety, effectiveness and controllable quality.

The present invention is directed to a monoclonal antibody that binds specifically to a Staphylococcus aureus glucosaminidase and inhibits in vivo growth of S. aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating 5*. aureus infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.

The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.

The invention provides an application of a perylene tetracarboxylic dianhydride amidation compound in anti-staphylococcus aureus. The compound is simple to prepare, a perylene tetracarboxylic dianhydride compound and N,N-dimethylethylenediamine are used as raw materials, multiple steps are carried out, the compound can inhibit the growth of staphylococcus aureus, and the bacteriostasis circle of the compound is up to about 10 mm measured by the K-B method. The compound is subjected to 2-fold gradient dilution, and the measured minimum inhibitory concentration (MIC) against staphylococcus aureus is up to 6.25 mg/mL. The growth curve inhibition test shows that when a growth curve of the bacteria in the non-drug treatment group enters the logarithmic phase, a growth curve of the bacteria in the compound treatment group is still in the lag phase, and indicates that the compound can inhibit the division of staphylococcus aureus. The discovered compound in the future can be used for the control of staphylococcus aureus infection, can also be applied in the preparation of antibacterial biomaterials, and has certain application value.

The invention discloses an application of a carbon quantum dot-graphite phase like carbon nitride photocatalytic material to preparation of medicines capable of killing bacteria and promoting skin cicatrice healing. A preparation method of the material comprises the following steps of placing urea at the temperature of 500-600 DEG C for calcination so as to obtain graphite phase carbon nitride powder; enabling citric acid and ethylenediamine to dissolve in water, performing a hydrothermal synthesis reaction at 180-200 DEG C, performing cooling, and performing drying so as to obtain carbon quantum dot powder; and mixing the carbon quantum dot powder with water, adding the graphite phase carbon nitride powder to mixed liquor, performing stirring and macerating at the temperature of 15-60 DEGC for 12-24 hours, and performing drying so as to obtain the catalysis material. According to the application disclosed by the invention, an in vitro staphylococcus aureus infection model and an in vitro staphylococcus aureus infection model are constructed, the inventor finds that the carbon quantum dot-graphite phase like carbon nitride photocatalytic material prepared by a specific method hasmore photocatalytic reaction active sites, is higher in photocatalytic activity and is obvious in the effect of killing staphylococcus aureus.

The present invention provides a method of preventing or treating bacteremia caused by Staphylococcus aureus, comprising administering a monoclonal or polyclonal antibody composition comprising antibodies specific for one or more S. aureus antigens. In one specific embodiment, the composition is a hyperimmune specific IGIV composition. In another specific embodiment, the composition comprise antibodies to a capsular polysaccharide S. aureus antigen, such as the Type 5 and/or Type 8 antigens. In another embodiment, the composition comprises monoclonal antibodies to a capsular polysaccharide S. aureus antigen. This method provides an effective tool for preventing or treating S. aureus bacteremia, and can be used alone or in combination with other therapies.

The invention provides lipopeptid which comprises a peptide chain and an aliphatic chain which are connected through peptide bonds, wherein the molecular weight of the lipopeptid is 2848Da, and the lipopeptid is linear, and can obviously introduce the expression of phylaxin, and effectively inhibit staphylococcus aureus infection so as to prevent or reduce skin infection. The invention also discloses a derivative of the lipopeptid and preparation methods and application of the lipopeptid and the derivative of the lipopeptid.

The invention provides a genetic engineering-modified staphylococcus aureus staphylophage lyase, the amino acid sequence of which is shown in SEQ ID NO:1. The invention also discloses a preparation method of the staphylococcus aureus staphylophage lyase, comprising the following concrete steps: (1) cloning the amino acid sequence shown in the SEQ ID NO:1 into a prokaryotic expression vector to obtain a recombinant plasmid; (2) transforming the recombinant plasmid obtained in the step (1) into host bacteria to obtain recombinant bacteria; (3) expressing the staphylococcus aureus staphylophage lyase by the recombinant plasmid; and (4) purifying the staphylococcus aureus staphylophage lyase obtained in the step (3). Multiple staphylococcus aureus can be specifically inactivated by independently using the genetic engineering-modified staphylococcus aureus staphylophage lyase or matching the genetic engineering-modified staphylococcus aureus staphylophage lyase with other compounds, thus providing a safe enzymic preparation source without toxic and side effects for staphylococcus aureus infection, particularly staphylococcus aureus caused dairy mastitis in the existing dairy farm control.

The invention discloses an antibody against staphylococcal enterotoxin B and application thereof. The heavy chain of the antibody against staphylococcal enterotoxin B has variable regions CDR1, CDR2 and CDR3 of which the amino acid sequences are shown in SEQ ID NO. 5, SEQ ID No. 6 and SEQ ID No. 7, or is composed of CDR variants with equivalent functions; and light chain of the antibody against staphylococcal enterotoxin B has variable regions CDR1, CDR2 and CDR3 of which the amino acid sequences are shown in SEQ ID NO. 9, SEQ ID No. 10 and SEQ ID No. 11, or is composed of CDR variants with equivalent functions. The antibody against staphylococcal enterotoxin B is capable of specifically binding with staphylococcal enterotoxin B or free enterotoxin B; and thus, the antibody can be used fortreating, preventing and diagnosing staphylococcus aureus infection. Therefore, the antibody against staphylococcal enterotoxin B will be an important research direction in the fields of "non-antibiotic" treatment of methicillin-resistant staphylococcus aureus infection and drug resistance development control.

The invention discloses derivatives of naftifine hydrochloride as well as a preparation method and application thereof. The derivatives of naftifine hydrochloride are as shown in the formula I. By inhibiting expression and/or function of key catalyzing enzyme CrtN in a golden yellow pigment synthesis pathway and powerfully inhibiting synthesis of golden yellow pigment, virulence of bacteria can be lowered. The key catalyzing enzyme CrtN in the golden yellow pigment synthesis pathway can be taken as a drug acting target; and compounds capable of inhibiting expression and/or function of key catalyzing enzyme CrtN can be used for preparing anti-bacterial drug. The naftifine hydrochloride and the derivatives thereof can be used as inhibitors for catalyzing enzyme CrtN to powerfully inhibit synthesis of the golden yellow pigment, so that the virulence of staphylococcus aureus can be lowered, and therefore, the derivatives can be used for preparing the anti-bacterial drug, especially drug for resisting staphylococcus aureus infection.

The invention discloses staphylococcus aureus bacteriophage and application. The staphylococcus aureus bacteriophage and the application have the advantages that staphylococcus aureus can be specifically effectively eliminated by the staphylococcus aureus bacteriophage, excellent in-vivo and in-vitro antibacterial effects can be realized by the staphylococcus aureus bacteriophage for medicine-resistant staphylococcus aureus, experimental foundations can be provided to clinically developing preparations for preventing and treating medicine-resistant staphylococcus aureus infection, and the staphylococcus aureus bacteriophage has great clinical application potential; the skin abscess average areas of nude mice of bacteriophage treatment groups are 47.32 mm<2> in skin abscess models when MOI(multiplicity of infection) is equal to 10, and the average bacterium load is 3.553*10<7> CFU/g; the skin abscess average areas of nude mice of MRSA (methicillin-resistant staphylococcus aureus) infection groups are 150.4 mm<2>, and the average bacterium load is 2.284*10<8> CFU/g; the skin abscess areas of the mice of the bacteriophage treatment groups are smaller than the skin abscess areas of the mice of the MRSA infection groups, the colony count of the mice of the bacteriophage treatment groups is lower than the colony count of the mice of the MRSA infection groups, and the difference of the skin abscess areas and the colony count has statistical significance.

The invention discloses an antibody for resisting staphylococcus aureus toxin and applications thereof, and relates to the technical field of antibodies. According to the antibody or a fragment thereof which is specifically combined with staphylococcus aureus toxin, the antibody or the fragment thereof can be specifically combined with a staphylococcus aureus gamma-hemolysin H1gB component, and can generate a cross reaction with other hemolysin components of the the hemolysin. The antibody comprises a variable region of heavy chain (VH) and a variable region of light chain (VL), wherein the variable region of heavy chain (VH) comprises the following CDR combination: VH-CDR1, VH-CDR2 and VH-CDR3, and the variable region of light chain (VL) comprises the following CDR combination: VL-CDR1, VL-CDR2 and VL-CDR3. The present invention can exert the effect of neutralizing, at least including neutralizing H1gB two-component toxin, thereby achieving the treatment of staphylococcus aureus infection alone or in combination with anti-staphylococcus aureus chemical drugs.

The invention discloses a staphylococcus aureus ITC (Inverse Transition Cycling) fusion protein which is a protein formed by fusing IsdB immunodominance fragments (IsdBid) and Trap as well as a ClfA immunodominance fragment N3 area (ClfAN3); an amino acid sequence of the fusion protein is as shown in SEQ ID NO.2. The invention further provides a coding gene, a preparation method and application of the fusion protein in preparing a vaccine for preventing staphylococcus aureus infection. The ITC fusion protein disclosed by the invention contains various antigens, and therefore, immune effect is good, protective effect of preventing staphylococcus aureus infection is improved; compared with the immune result of any of ClfA, IsdB and TraP, the ITC fusion protein immune effect is better than that of single protein; moreover, the ITC contains Trap with smaller molecular weight and has an immunodominance fragment with two antigens, so that peptide chain length is not lengthy, and therefore, the fusion protein is beneficial to in-vitro expression and has important value in developing and applying a novel vaccine for preventing staphylococcus aureus.

The invention relates to the application of naringenin in the preparation of medicine for curing pneumonia. The effect in staphylococcus aureus infection curing is proved through a rabbit erythrocyte hemolytic test, a pulmonary epithelial cell (A549) damage protection test and a mouse staphylococcus aureus pulmonary inflammation model. Compared with antibiotic therapy, naringenin therapy has the characteristics of no drug tolerance and high cure rate.

The invention relates to a pharmaceutical composition for treating staphylococcus aureus infection. The pharmaceutical composition contains chlorogenic acid and glycyrrhizic acid. The pharmaceutical composition substantially inhibits staphylococcus aureus activity and substantially improves staphylococcus aureus inhibition effects of an antibiotic. The invention also provides a use of the pharmaceutical composition. The pharmaceutical composition is used for preparation of a drug for treating staphylococcus aureus infection and/or preparation of a drug for killing staphylococcus aureus in the environment.

The invention discloses a novel anti-staphylococcus aureus polyclonal antibody for treating staphylococcus aureus infection. The antibody is obtained by immunizing a New Zealand white rabbit with staphylococcus aureus MntC protein as a major immunizing antigen. The novel anti-staphylococcus aureus polyclonal antibody has an immune regulation effect and is capable of promoting the phagocytosis of the organism to the staphylococcus aureus so as to achieve the effect of treating the staphylococcus aureus infection.

The invention relates to staphylococcus aureus FnBPA-A protein mimic epitope peptides having immunizing protection, a mimic epitope peptide composition, and applications of the mimic epitope peptides and the mimic epitope peptide composition. Two immunoprotective mimic epitope peptides provided by the invention have the amino acid sequences respectively shown in SEQ ID NO:1 and SEQ ID NO:2, the mimic epitope peptide composition consists of two polypeptides shown in SEQ ID NO:1 and SEQ ID NO:2, and the mass ratio of the polypeptide shown in SEQ ID NO:1 to the polypeptide shown in SEQ ID NO:2 is 2 to 1. Experiment animal immunoprotective tests show that the two mimic epitope peptides can stimulate a body to produce high-level specific antibodies and have a certain degree of immunizing protection; moreover, the mimic epitope peptide composition has the immunoprotective effect on staphylococcus aureus infection better than that of an FnBPA-A holoprotein. Therefore, the mimic epitope peptides and the composition thereof can be used as effective components for development of multi-epitope vaccines of staphylococcus aureus and prevention of cow mastitis caused by staphylococcus aureus.

The invention discloses an anti-Staphylococcus aureus eLtaS protein monoclonal neutralizing antibody E4-2, belonging to the technical field of preparation of antibodies for immunization. An antibody light/heavy chain variable region gene is cloned from the prepared eLtaS neutralizing monoclonal antibody E4-2, and can code correct mouse antibody variable regions. The light/heavy chain variable region gene based on the monoclonal antibody can be used for constructing and expressing multiple micromolecule gene engineering antibodies; and the polypeptide or protein coded on the basis of the gene can crosslink multiple biological activity molecules for preparing anti-Staphylococcus aureus infection drugs, and has wide application prospects.

The invention discloses a recombinant plasmid of a GSDMD-N (gasdmermin D-N) gene, an expression method in mammary gland and an application, and belongs to the field of genetic engineering. An expression recombinant plasmid of the GSDMD-N gene is constructed and enabled to be specifically expressed in breast tissue and breast cells, so that mastitis caused by staphylococcus aureus infection is prevented and treated. GSDMD-N protein is a polypeptide compound found in recent years, which can specifically recognize biofilm component cardiolipin of bacteria and can be combined with cardiolipin to form a plurality of honeycomb-shaped pores, so that bacteria are disintegrated and die. According to the technology, the exogenous gene GSDMD-N is efficiently expressed in animal mammary glands througha specific promoter WAP (whey acidic protein) of breast tissue by a mammary bioreactor, staphylococcus aureus causing cow mastitis is killed, and accordingly, the cow mastitis caused by staphylococcus aureus infection is prevented and treated. The recombinant plasmid and the recombinant attenuated salmonella have the advantages of being efficient, safe, low in cost and the like, provide a a new approach for prevention and control of the cow mastitis caused by staphylococcus aureus infection, and have good application prospect.

The invention relates to psoralen schiff base derivatives and an application. The compounds are 4-methyl-7-hydroxycoumarin (which is an intermediate 1), 4-methyl-7-hydroxyethoxycoumarin (which is an intermediate 2), 4-methyl-7-formylmethoxycoumarin (which is an intermediate 3), 5-methyl-7H-furan[3,2-g]benzopyran-7-one (which is a compound 4), 7-oxo-7H-furan[3,2-g]benzopyran-5-formaldehyde (which is a compound 5), and a compound 6a-6k. The fact that the 11 psoralen schiff base derivatives affect generation of melanin in mouse B16 cells and inhibit candida albicans, escherichia coli, and staphylococcus aureus is studied. The resultant compounds 6a-6b, 6d-6f and 6j-6k can be applied to prepare medicines for treating vitiligo in the clinic. The obtained psoralen schiff base derivatives can be used for preparing medicines for treating candida albicans infection in the clinic, and the compounds 6b-6c, 6e-6h and 6h-6k can be used for preparing medicines for treating staphylococcus aureus infection in the clinic.

The present composition combines an RNAIII-inhibiting peptide (RIP) with an antimicrobial peptide, such as a cathelicidin, that is capable of binding and neutralizing lipidic and polyanionic components of bacterial cell envelope. In another embodiment, the RIP is combined with an antibiotic, with or without an antimicrobial peptide. The present composition is advantageously used in a method of treatment of bacterial sepsis.

The invention discloses a staphylococcus aureus capsular polysaccharide and protein conjugate and preparation method and application thereof. Salmonella typhimurium flagellin or polylysine salmonella typhimurium flagellin is taken as a carrier, and staphylococcus aureus capsular polysaccharide is subject to chemical modification, and then chemical coupling is carried out on the staphylococcus aureus capsular polysaccharide and the carrier protein. As the salmonella typhimurium flagellin and polylysine salmonella typhimurium flagellin have immunologic adjuvant function, the new formed conjugate can cause staphylococcus aureus capsular polysaccharide with extremely low immunogenicity to have higher immunogenicity, and the carrier protein plays the immunologic adjuvant function when in inoculation, so that specific immune response of immune animal to the staphylococcus aureus capsular polysaccharide is enhanced. The invention has wide application in preparation of vaccine resisting staphylococcus aureus infection.